The global biologics drug development market was estimated at $2.79 billion in 2017 and is expected to grow over $8.46 billion by 2027.
With the increasing life expectancy and changing lifestyle of the world population, the healthcare needs across the world are changing. Physical inactivity, rising obesity, and stress along with an increase in geriatric population is expected to raise the predisposition toward the chronic diseases. The introduction of biological therapies gave a new ray of hope for people suffering from chronic diseases. The primary reason for such a shift toward biologic products is better efficacy, absence of innovator small molecule drugs, better interaction with the target as well as specificity toward targets. The entry of biosimilars makes these effective therapies more affordable, though the concern regarding their after effects still exists.
The introduction of targeted therapies coupled with rising adoption of patient-centric personalized medicine is expected to fuel the demand for biologics drugs in the future. Moreover, ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories in the development of novel therapeutic biologic drugs. The increasing biologics approval each year indicate the effectiveness of these products.
The purpose of the study is to gain a holistic view of the biologics drug development market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the biologics drug development market. The market has been segmented into product class', facility', services', and geographical regions'.
Based on the product class, monoclonal antibody is anticipated to be the major contributor to the market. The next contributing segment is vaccines. However, the fastest growing segment is expected to be growth factors market.
The market can be further segmented based on facility into in-house, outsource, and PharmaExcess. The in-house manufacture of biologics is the dominant manufacturing facility as most of the biologics production and manufacture is done in-house by biopharmaceutical companies. However, PharmaExcess is expected to grow at the highest CAGR during the forecast period.
Based on services the market can be segmented into clinical manufacturing, formulation development, bioassay development, and analytical services. Clinical manufacturing is the dominant segment with the highest revenue contribution as well as the highest CAGR value for the forecast period from 2018 to 2027.
Geographically, the largest contributor to the growth of the global biologics drug development market in 2017 was North America due to the presence of pharmaceutical companies involved in R&D of biologics. North America was followed by Europe in terms of growth. However, the fastest growing region was Asia-Pacific due to the increasing presence of Contract Research Organisations (CRO).
The biologics drug development market presents with opportunities to change the treatment options. The development of antibody drug conjugates, glycosylated antibodies, Chimeric Antigen Receptor-T (CAR-T) cell therapy, and bio-betters presents opportunities for the further growth of the biologics drug development market.
The answers to the following key questions can be derived from this report:
What are the major market drivers, challenges, and opportunities in the global biologics drug development market and their case studies?
What were the market shares of the leading segments and sub-segments of the global biologics drug discovery market in 2017, and what will be the shares in 2027?
How will each segment of the global biologics drug development market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2027?
What are the influencing factors that may affect the market share of the key players?
How will the industry evolve during the forecast period between 2017 and 2027?
What are the key developmental strategies implemented by the key players to stand out in this market?
What will be the growth rate of the PharmaExcess segment during the forecast period?
Who are the key outsourced manufacturers of the biologics drug development market?
How the market has been segmented on the basis of services? Which service is highly adopted in the biologics drug development process?
Which geographical location will contribute to the highest revenue generation of the biologics drug development market?
The key players of the market include Abbvie, Inc., Allergan Plc, Boehringer Ingelheim International GmbH, Charles River Laboratories, Catalent Inc., Lonza Group, MabPlex Inc., Samsung Biologics, and Amgen, Inc., among others.
Key Topics Covered:
1 Market Overview 1.1 Biologics Drug Development 1.2 Biologics Drug Development: Key Trends 1.3 Integrated Discovery, Development, and commercialization of Biologics 1.4 Clinical Developmental Stages of Biologics 1.5 Manufacturing Stages of Biologics 1.6 Process Development 1.7 Bio Manufacturing Process 1.8 Formulation Development 1.9 Biologics In-House Drug Development Market 1.9.1 North America 1.9.2 Europe 1.9.3 Asia-Pacific 1.10 Biologics Outsourcing Drug Development Market 1.10.1 North America 1.10.2 Europe 1.10.3 Asia-Pacific 1.11 Biologics Drug Development Cost
3 Competitive Landscape 3.1 Key Developmental Strategies 3.1.1 Acquisitions 3.1.2 Agreements, Partnership, Collaboration and Joint Ventures 3.1.3 Approvals 3.1.4. Clinical Study 3.1.5 Business Expansion 3.1.6 Product Launch 3.1.7 Awards 3.2 Porter's Five Forces Analysis
4 Biologics Drug Development Market, (by Class) 4.1 Overview 4.1.1 Monoclonal Antibodies (mAbs) 4.1.2 Hormones 4.1.3 Growth Factors 4.1.4 Cytokines and Fusion Proteins 4.1.5 Therapeutic Enzymes 4.1.6 Blood Factors and Anticoagulants 4.1.7 Vaccines
5 Biologics Drug Development Market, (by Facility) 5.1 Overview 5.1.1 In-House 5.1.2 Outsource 5.1.3 Pharma Excess
6 Biologics Drug Development Market, (by Services) 6.1 Overview 6.1.1 Clinical Manufacturing 184.108.40.206 Cell Bank Preparation and Cell Line Development 220.127.116.11 Cell Culture Upstream Development 18.104.22.168 Purification Downstream Development 6.1.2 Formulation Development 6.1.3 Bioassay Development 6.1.4 Analytical Services
7 Biologics Drug Development Market, (by Region) 7.1 Global Scenario 7.2 North America 7.2.1 The U.S. 7.2.2 Canada 7.3 Europe 7.3.1 The U.K. 7.3.2 Germany 7.3.3 France 7.3.4 Switzerland 7.3.5 Rest-of-Europe 7.4 Asia Pacific 7.4.1 Japan 7.4.2 China 7.4.3 South Korea 7.4.4 India 7.4.5 Rest-of-Asia-Pacific 7.5 Rest-of-the-World (RoW)
8 Company Profiles 8.1 AbbVie Inc. 8.2 Allergan 8.3 Amgen, Inc. 8.4 Boehringer Ingelheim International GmbH 8.5 Catalent Inc. 8.6 Charles River Laboratories 8.7 FUJIFILM Diosynth Biotechnologies U.S.A., Inc 8.8 KBI Biopharma 8.9 Lonza 8.10 MabPlex Inc. 8.12 Samsung BioLogics 8.13 SANOFI 8.14 Singota Solutions 8.15 WuXi Biologics
9 Consumer Perception (Pharmaceutical Companies) on Clinical Manufacturing of Biologics Drugs
10 Report Scope and Methodology 10.1 Scope of the Report 10.2 Global Biologics Drug Development Market Segmentation 10.3 Research Methodology 10.3.1 Data Triangulation 10.3.2 Key Data Points from Secondary Sources 10.3.3 Key Data Points from Primary Sources 10.3.4 Top-Down Approach (Segmental Analysis) 10.3.5 Bottom-Up Approach (Segmental Analysis) 10.4 Assumptions and Limitations 10.5 Data and Prediction Modelling